Serum CA242, CA199, CA125, CEA, and TSGF are Biomarkers for the Efficacy and Prognosis of Cryoablation in Pancreatic Cancer Patients

Abstract

This study aimed to compare the changes and determine the clinical significance of carbohydrate antigens CA242, CA199, CA125, carcinoembryonic antigen (CEA), and tumor-specific growth factor (TSGF) before and after cryoablation by Cryocare system. Thirty-one pancreatic cancer patients were selected to receive cryoablation by Cryocare system. The serum expression levels of CA242, CA199, CA125, CEA, and TSGF before and 1 month after treatment were determined. Meanwhile, the serum level of these factors was also determined in 31 healthy volunteers. The parameter changes were analyzed with the clinical pathological data. The serum levels of CA242, CA199, CA125, CEA, and TSGF in the pancreatic cancer group were significantly higher than those of the control group both before and after the cryoablation treatment (P < 0.05). The serum CA199, CEA, and TSGF dramatically decreased 1 month after the treatment, which were statistically different (P < 0.05). The positive rates of serum CA242, CA199, CA125, and CEA in the pancreatic cancer group were much higher than those in the control group both before and after treatment (P < 0.05), and the positive rate of TSGF was significantly higher than that of the control group before the treatment (P < 0.05). The positive rate of CA199, CEA, and TSGF after the treatment was significantly lower than that before the treatment (P < 0.05). Serum level of CA242 was correlated with the tumor diameter, clinical staging, tumor differentiation, lymph node, and liver metastasis (P < 0.05). Except gender, CA199 was correlated with all the other clinical pathological parameters (P < 0.05). The serum levels of CA125 and CEA were correlated with all the other clinical pathological parameters (P < 0.05). The serum level of TSGF was only correlated with tumor differentiation (P < 0.05). Cryoablation treatment by Cryocare system can decrease the serum levels of CA199, CEA, TSGF, and the positive rate. Serum CA199, CEA, and TSGF can be important index for pancreatic cancer treatment assessment. Serum levels of CA242, CA199, CA125, and CEA are of great clinical value for metastasis assessment and prognosis in pancreatic cancer patients.

Combined assays for serum carcinoembryonic antigen and microRNA-17-3p offer improved diagnostic potential for stage I/II colon cancer

“…To evaluate the diagnostic value of miR-17-3p and CEA that were identified in previous studies (16,17), serum samples of 70 stage I/II colon cancer patients and 70 healthy controls were examined by radioimmunoassay and RT-qPCR, respectively. miR-16 was used as the endogenous control, as it displayed high stability, high abundance and low variability in analyzed serum samples.…”

The clinical utility of CA125/MUC16 in pancreatic cancer: A consensus of diagnostic, prognostic and predictive updates by the Chinese Study Group for Pancreatic Cancer (CSPAC)

“…In addition, another recent study revealed the co-expression of CA125 and mesothelin in PC, which was associated with a poor prognosis due to the related initiation of intracavitary tumor metastasis (23). Not only CA125 alone, but other serum tumor biomarkers such as CA242, CA19-9 and CEA, when used as prognostic tools, may also be of great clinical value for the efficacy and prognosis of specific treatments for patients with PC, with the possibility of recurrence and metastasis (8).…”

“…Due to limited sensitivity and specificity, the measurement of a single tumor biomarker is usually not sufficient to evaluate tumor development (30,74). Certain studies have indicated that the serum levels of individual biomarkers, such as CA125, CEA, CA19-9, and CA242 are not associated with tumor size (8). However, patients with high expression levels of these markers presented with late-stage disease, which demonstrated that a comprehensive assessment of various biomarkers, to provide more biological information, was necessary (8,31,43).…”

“…Certain studies have indicated that the serum levels of individual biomarkers, such as CA125, CEA, CA19-9, and CA242 are not associated with tumor size (8). However, patients with high expression levels of these markers presented with late-stage disease, which demonstrated that a comprehensive assessment of various biomarkers, to provide more biological information, was necessary (8,31,43). In previous studies, the multi-analysis of different biomarkers [CA19-9, neuron specific enolase (NSE), CEA, CA242, CA125, circulating tumor cells and ctDNA] was more useful in the diagnosis and prognosis of PC, and was superior to that of any single biomarker (75,76).…”

“…The serum levels of CA125 have been widely used in ovarian cancer for diagnosis, the detection of early recurrence, and for the monitoring of the therapeutic effects of treatments (4)(5)(6). Recently, studies on the use of CA125/MUC16 in patients with PC treated with resection, radiotherapy or chemotherapy have been published, and may assist in the diagnosis and treatment of this type of cancer (7)(8)(9). The Chinese Study Group for pancreatic Cancer (CSpAC) has provided a consensus on the use of the biomarker CA125/MUC16, its biological significance and its clinical applicability, in order to facilitate the optimization of treatment strategies for pC.…”